Tranexamic%252525252525252525252525252525252525252525252520acid

# Tranexamic Acid ## Overview Tranexamic acid (TXA) is a synthetic lysine analog that acts as a potent antifibrinolytic agent. It competitively inhibits the activation of plasminogen to plasmin, thereby preventing the degradation of fibrin clots. ## Primary Indications * **Trauma:** Management of severe hemorrhage (CRASH-2 protocol). * **Surgery:** Prevention and treatment of excessive blood loss in cardiac, orthopedic, and gynecological surgery. * **Obstetrics:** Management of postpartum hemorrhage (PPH) or heavy menstrual bleeding (HMB). * **Dentistry:** Hemostasis in patients with congenital coagulopathies (e.g., hemophilia) undergoing dental extractions. ## Adult Dosing * **Trauma/Acute Hemorrhage:** 1 g IV bolus over 10 minutes, followed by 1 g IV infusion over 8 hours. Administer within 3 hours of injury. * **Postpartum Hemorrhage:** 1 g IV slowly (1 mL/min). A second 1 g dose may be administered if bleeding persists or recurs after 30 minutes. * **Heavy Menstrual Bleeding:** 1.3 g orally TID for up to 5 days during menstruation. * **Dental (Hemophilia):** 10 mg/kg IV prior to extraction, followed by 25 mg/kg orally TID-QID for 2–8 days. ## Pediatric Dosing * **Trauma/Hemorrhage:** 15 mg/kg (max 1 g) IV loading dose, followed by 2 mg/kg/hour infusion until bleeding is controlled. * **Congenital Coagulopathies:** 25 mg/kg orally TID-QID or 10 mg/kg IV TID-QID. * *Note: Off-label use; consult institutional protocols for specialized pediatric weight-based dosing.* ## Dose Adjustments * **Renal Impairment:** Requires reduction in dose and frequency based on serum creatinine/eGFR. Refer to package insert for specific CrCl-based maintenance infusion adjustments. No adjustment is typically required for the initial bolus in trauma. * **Hepatic Impairment:** No specific adjustment required; use with caution. ## Contraindications * History of active thromboembolic disease (DVT, PE, cerebral thrombosis). * Acquired disturbances of color vision (caution). * Subarachnoid hemorrhage (risk of cerebral edema/seizures). * Known hypersensitivity to tranexamic acid. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain. * **Serious:** Thromboembolic events (PE, DVT, MI, stroke), seizures (particularly with high-dose IV administration during cardiac surgery), visual disturbances, and allergic reactions (anaphylaxis). ## Key Drug Interactions * **Prothrombotic agents:** Increased risk of thrombosis when combined with Factor IX complex concentrates or anti-inhibitor coagulant complexes. * **Thrombolytics:** Concurrent use with thrombolytic agents (e.g., alteplase) may antagonize the effect of the thrombolytic. * **Oral Contraceptives:** Potential increased risk of thrombosis if taken together. ## Monitoring * **Clinical:** Monitor for signs of venous or arterial thrombosis (e.g., chest pain, dyspnea, extremity swelling). * **Neurological:** Monitor for seizures, especially at high doses or in patients with pre-existing seizure disorders. * **Ophthalmological:** Perform eye exams if long-term treatment is necessary. * **Renal:** Monitor renal function in patients with pre-existing impairment. ## Clinical Pearls * **Timing is critical:** Efficacy in trauma patients diminishes significantly if administered more than 3 hours after injury. * **Administration:** Never administer IV bolus too rapidly (<1 mL/min/1g) as this may cause hypotension/dizziness. * **Incompatibility:** Do not mix with blood products or penicillin-containing solutions in the same IV line. * **Regional Protocols:** Always verify dosing against current local institutional protocols, as obstetric and trauma guidelines vary globally. *** *Disclaimer: This information is for educational purposes only and does not constitute medical advice. Dosing, contraindications, and product availability may change. Always verify specific drug information against the manufacturer's official prescribing information (package insert) or institutional formulary prior to clinical administration.*